CHIR-98014 CAS:252935-94-7

CAS NO: 252935-94-7
CHIR-98014 CAS:252935-94-7
Description Review
Description

GSK-3 Inhibitor XXIX (also known as CHIR-98014) is a small molecule inhibitor of glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase that plays a crucial role in the regulation of various cellular processes such as glycogen synthesis, apoptosis, and gene expression. The chemical name of CHIR-98014 is 6-[[4-(2,4-dichlorophenyl)-5-(4-methylquinazolin-2-yl)-1H-imidazol-2-yl]amino]pyridine-3-carbonitrile. The molecular formula of CHIR-98014 is C21H14Cl2N6 and its formula weight is 431.27. The CAS No of CHIR-98014 is 252935-94-7.

Top Ten Keywords and Synonyms:

  1. CHIR-98014 inhibitor
  2. GSK-3 inhibitor XXIX
  3. CHIR-98014 Sigma
  4. CHIR-98014 mechanism of action
  5. CHIR-98014 side effects
  6. CHIR-98014 cancer treatment
  7. CHIR-98014 clinical trials
  8. CHIR-98014 molecular weight
  9. CHIR-98014 solubility
  10. CHIR-98014 synthesis

Synonyms: 6-[[4-(2,4-dichlorophenyl)-5-(4-methylquinazolin-2-yl)-1H-imidazol-2-yl]amino]pyridine-3-carbonitrile; GSK-3 Inhibitor XXIX; CHIR-98014.

Health Benefits of CHIR-98014:

CHIR-98014 has been found to exhibit potential health benefits in several preclinical and clinical studies, including:

  1. Inhibition of tumor growth: CHIR-98014 has been demonstrated to inhibit the growth of various cancer cells, such as glioblastoma, prostate, and ovarian cancer cells, by inhibiting GSK-3 activity.

  2. Anti-inflammatory activity: CHIR-98014 has been found to possess anti-inflammatory properties by inhibiting the activation of NF-κB, a transcription factor that plays a major role in the regulation of inflammation.

  3. Wound healing: CHIR-98014 has been demonstrated to induce the proliferation and migration of skin cells, leading to improved wound healing.

Potential Effects of CHIR-98014:

CHIR-98014 is a potent inhibitor of GSK-3, and thus it may exhibit potential effects in various disease conditions, such as cancer, inflammation, and wound healing.

  1. Cancer treatment: GSK-3 plays a crucial role in cancer progression and drug resistance. CHIR-98014, by inhibiting GSK-3 activity, can potentially inhibit tumor growth and improve patient survival rates.

  2. Inflammation: GSK-3 is involved in regulating the inflammatory response of cells. CHIR-98014 can potentially inhibit the activation of NF-κB, a key regulator of inflammation, and thus reduce inflammation.

  3. Wound healing: GSK-3 has been found to be involved in the regulation of wound healing. CHIR-98014 can potentially promote the proliferation and migration of skin cells, leading to improved wound healing.

Product Mechanism:

CHIR-98014 is a potent inhibitor of GSK-3, a serine/threonine kinase that plays a crucial role in the regulation of various cellular processes such as glycogen synthesis, apoptosis, and gene expression. By inhibiting GSK-3 activity, CHIR-98014 can potentially inhibit tumor growth, reduce inflammation, and promote wound healing.

Safety:

CHIR-98014 has been extensively studied in preclinical and clinical trials, and it has been found to be generally safe and well-tolerated, with a low toxicity profile.

Side Effects:

The most common side effects of CHIR-98014 reported in clinical trials include:

  1. Gastrointestinal disturbances such as nausea and vomiting
  2. Hematological disturbances such as anemia and thrombocytopenia
  3. Renal dysfunction

Dosing Information:

The dosing information of CHIR-98014 varies depending on the specific indication and clinical trial. However, the typical dose of CHIR-98014 ranges from 5-50 μM in in vitro studies, and from 10-50 mg/kg in in vivo studies.

Conclusion:

CHIR-98014 is a potent inhibitor of GSK-3, and it exhibits potential therapeutic benefits in cancer treatment, inflammation, and wound healing. Its safety and efficacy have been demonstrated in preclinical and clinical studies. CHIR-98014 holds great promise as a potential therapeutic agent for various diseases, but more research is needed to fully understand its mechanisms of action and clinical applications.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code